Table 1.
List of Jakinibs with therapeutic potential in treatment of Systemic Lupus and Systemic Sclerosis.
| JAK Inhibitor Name | Selectivity | Indication (NCT Study) |
|---|---|---|
| Tofacitinib | Non-selective | Tested for lupus treatment (NCT02535689, NCT05048238, and NCT03288324) |
| Baricitinib | Non-selective | Studies in Lupus terminated (NCT03616912, NCT03843125) |
| Ruxolitinib | Non-selective | Trial in DLE (NCT04908280) |
| Peficitinib | Non-selective | Tested for RA treatment |
| Filgotinib | Jak-1 selective | Assessed for treatment of CLE (NCT03134222) |
| Upadacitinib | Jak-1 selective | Evaluated for lupus treatment (NCT04451772 and NCT03978520) |
| Solcitinib | Jak-1 selective | Study in SLE terminated NCT01777256 |
| Itacitinib | Jak-1 selective | Under investigation in Systemic Sclerosis (NCT04789850) |
| AC430 | Jak-2 | Potential role in the treatment of cancer and autoimmune diseases |
| TG101209 | JAK-2 | Potential role in the treatment of leukaemias and myeloproliferative disorders |
| Decernotinib | JAK-3 | Tested for treatment in RA |
| R 333 | Jak-3 | Further studies terminated |
| PF 06651600Ritlecitinib | JAK-3 (dual JAK-3/TEC inhibitor) | Evaluated in alopecia areata, RA |
| Brepocitinib | JAK-1/Tyk2 | Tested in SLE (NCT03845517) |
| Deucravacitinib | Tyk-2 | Assessed in SLE (NCT03252587) (NCT03920267) |
TEC tyrosine kinase expressed in hepatocellular carcinoma; DLE discoid lupus erythematosus; CLE cutaneous lupus erythematosus.